BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 43.99 USD 2.71%
Market Cap: 8.4B USD

Intrinsic Value

BBIO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one BBIO stock under the Base Case scenario is 45.88 USD. Compared to the current market price of 43.99 USD, BridgeBio Pharma Inc is Undervalued by 4%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BBIO Intrinsic Value
45.88 USD
Undervaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Compare BBIO to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about BBIO?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about BridgeBio Pharma Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
BridgeBio Pharma Inc

Current Assets 695.2m
Cash & Short-Term Investments 540.6m
Receivables 115.3m
Other Current Assets 39.3m
Non-Current Assets 186.5m
Long-Term Investments 128.2m
PP&E 13.9m
Intangibles 27.8m
Other Non-Current Assets 16.6m
Efficiency

Free Cash Flow Analysis
BridgeBio Pharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
BridgeBio Pharma Inc

Revenue
127.4m USD
Cost of Revenue
-5.9m USD
Gross Profit
121.5m USD
Operating Expenses
-806.4m USD
Operating Income
-684.9m USD
Other Expenses
16.9m USD
Net Income
-668m USD
Fundamental Scores

BBIO Profitability Score
Profitability Due Diligence

BridgeBio Pharma Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Exceptional ROE
ROIC is Increasing
Exceptional Gross Margin
45/100
Profitability
Score

BridgeBio Pharma Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

BBIO Solvency Score
Solvency Due Diligence

BridgeBio Pharma Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Positive Net Debt
Long-Term Solvency
34/100
Solvency
Score

BridgeBio Pharma Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BBIO Price Targets Summary
BridgeBio Pharma Inc

Wall Street analysts forecast BBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BBIO is 61.38 USD with a low forecast of 42.42 USD and a high forecast of 99.75 USD.

Lowest
Price Target
42.42 USD
4% Downside
Average
Price Target
61.38 USD
40% Upside
Highest
Price Target
99.75 USD
127% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

BridgeBio Pharma Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BBIO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

BBIO Insider Trading
Buy and sell transactions by insiders

BBIO News

Other Videos
What is the Intrinsic Value of one BBIO stock?

The intrinsic value of one BBIO stock under the Base Case scenario is 45.88 USD.

Is BBIO stock undervalued or overvalued?

Compared to the current market price of 43.99 USD, BridgeBio Pharma Inc is Undervalued by 4%.

Back to Top